Management of hypertension and dyslipidemia

被引:0
|
作者
Keith C. Ferdinand
Myra A. Kleinpeter
机构
[1] Association of Black Cardiologists,
[2] Inc.,undefined
来源
关键词
Metabolic Syndrome; Carvedilol; Thiazide; Rosuvastatin; Beta Blocker;
D O I
暂无
中图分类号
学科分类号
摘要
Cardiovascular disease, the leading cause of death in the United States and other developed societies, can be managed with intensive risk factor modification, including treatment of hypertension and dyslipidemia. Evidence for reduction of cardiovascular morbidity and mortality is summarized in evidence-based guidelines, primarily for hypertension in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and for dyslipidemia in the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Many medications exist for treatment of hypertension and a limited number for dyslipidemia; the cornerstone of therapy for both remains lifestyle modification, including dietary interventions. Despite guidelines, control rates of concomitant hypertension and dyslipidemia remain low. Patient adherence may affect achievement of recommended goals of therapy for dyslipidemia and hypertension. Effective education and communication may improve overall achievement of treatment goals.
引用
收藏
页码:489 / 496
页数:7
相关论文
共 50 条
  • [41] Management of dyslipidemia in children
    Kalra, Sanjay
    Gandhi, Arun
    Kalra, Bharti
    Agrawal, Navneet
    DIABETOLOGY & METABOLIC SYNDROME, 2009, 1
  • [42] Management of dyslipidemia in adults
    Ahmed, SM
    Clasen, ME
    Donnelly, JF
    AMERICAN FAMILY PHYSICIAN, 1998, 57 (09) : 2192 - 2204
  • [43] MANAGEMENT OF PATIENTS WITH DYSLIPIDEMIA
    MANN, J
    CHISHOLM, A
    CROOKE, M
    JACKSON, R
    NEUTZE, J
    NORTH, D
    SWINBURN, B
    WHITE, H
    WILCOX, J
    NEW ZEALAND MEDICAL JOURNAL, 1995, 108 (1010) : 444 - 444
  • [44] Contemporary Management of Dyslipidemia
    Richard A. Ferraro
    Thorsten Leucker
    Seth S. Martin
    Maciej Banach
    Steven R. Jones
    Peter P. Toth
    Drugs, 2022, 82 : 559 - 576
  • [45] Hypertension and dyslipidemia among Iranian people
    Sarrafzadegan, N
    Boshtam, M
    Najafian, G
    Poorshams, A
    Samarian, H
    ATHEROSCLEROSIS, 1999, 144 : 150 - 151
  • [46] Exercise considerations in hypertension, obesity, and dyslipidemia
    MacKnight, JM
    CLINICS IN SPORTS MEDICINE, 2003, 22 (01) : 101 - +
  • [47] Therapeutic management of dyslipidemia
    不详
    ANNALES D ENDOCRINOLOGIE, 2001, 62 (01) : 70 - 75
  • [48] Management of dyslipidemia: An update
    Cynthia A. Sanoski
    Current Atherosclerosis Reports, 2003, 5 (4) : 284 - 290
  • [49] Advances in the management of dyslipidemia
    Kampangkaew, June
    Pickett, Stephen
    Nambi, Vijay
    CURRENT OPINION IN CARDIOLOGY, 2017, 32 (04) : 348 - 355
  • [50] THE SYNERGISTIC EFFECT OF OBESITY AND DYSLIPIDEMIA ON HYPERTENSION
    Izadi, Neda
    Mohseni, Miss Parisa
    ATHEROSCLEROSIS, 2024, 399 : 59 - 59